Thanks to a $250,000 grant from the National Multiple Sclerosis Society, Endece Neural, a subsidiary company of Mequon-based drug discovery company Endece LLC, is forging ahead with preclinical research of a drug compound that it believes could revolutionize treatment options for people living with multiple sclerosis (MS).
Read the full story here, in the Oct. 28 issue of BizTimes Milwaukee magazine.
